University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Susana Ortiz-Urda, M.D., Ph.D.

Dermatologist and melanoma specialist

Dr. Susana Ortiz-Urda, co-director of the UCSF Melanoma Center, treats patients with early and advanced melanoma. In her research, she leads a laboratory that is working to identify the mechanisms of early melanoma progression.

Ortiz-Urda earned a medical degree and doctorate at the University of Vienna in Austria. She completed a residency in dermatology and a postdoctoral fellowship in epithelial biology, both at Stanford University, followed by a cutaneous oncology fellowship in dermatology at UCSF. She is a member of the American Academy of Dermatology, Austrian Society of Dermatology and Venerology, and Dermatology Foundation. Ortiz-Urda has received several awards, including the Kardinal-Innitzer Award for Outstanding Science in Dermatology and the Unilever Award from the Austrian Society for Dermatology and Venerology. She is an assistant professor of dermatology at UCSF.

  • Hear an interview with Ortiz-Urda, who discusses new medications for the deadliest form of skin cancer.

Clinics

Dermatology Clinic
1701 Divisadero St., Third and Fourth Floors
San Francisco, CA 94115
Phone: (415) 353–7800
Fax: (415) 353–7870

Hours: Monday to Friday, 8 a.m. – 5 p.m.

Melanoma Center
1600 Divisadero St.,
San Francisco, CA 94115
Phone: (415) 353-9900
Fax: (415) 885-3802

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Susana Ortiz-Urda

Additional Languages

German
Spanish

Education

University of Vienna School of Medicine 1998

Residencies

UCSF Medical Center, Dermatology 2010
Stanford Medical Center, Dermatology 2010

Selected Research and Publications

  1. Posch C, Ortiz-Urda S. NRAS mutant melanoma--undrugable? Oncotarget. 2013 Apr; 4(4):494-5.
  2. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 5; 110(10):4015-20.
  3. Chong K, Daud A, Ortiz-Urda S, Arron ST. Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg. 2012 Jun; 31(2):140-9.
  4. Reuter JA, Ortiz-Urda S, Kretz M, Garcia J, Scholl FA, Pasmooij AM, Cassarino D, Chang HY, Khavari PA. Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression. Cancer Cell. 2009 Jun 2; 15(6):477-88.
  5. Waterman EA, Sakai N, Nguyen NT, Horst BA, Veitch DP, Dey CN, Ortiz-Urda S, Khavari PA, Marinkovich MP. A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation. Cancer Res. 2007 May 1; 67(9):4264-70.
  6. Ortiz-Urda S, Garcia J, Green CL, Chen L, Lin Q, Veitch DP, Sakai LY, Lee H, Marinkovich MP, Khavari PA. Type VII collagen is required for Ras-driven human epidermal tumorigenesis. Science. 2005 Mar 18; 307(5716):1773-6.
  7. Marker M, Ortiz-Urda S, Lilgenau N, Rappersberger K. [Erythema induratum-nodular vasculitis]. J Dtsch Dermatol Ges. 2004 Mar; 2(3):206-14; quiz 215.
  8. Valencak J, Ortiz-Urda S, Heere-Ress E, Kunstfeld R, Base W. Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema. Int J Dermatol. 2004 Jan; 43(1):51-4.
  9. Ortiz-Urda S, Elbe-Bürger A, Smolle J, Marquart Y, Chudnovsky Y, Ridky TW, Bernstein P, Wolff K, Rappersberger K. The plant lectin wheat germ agglutinin inhibits the binding of pemphigus foliaceus autoantibodies to desmoglein 1 in a majority of patients and prevents pathomechanisms of pemphigus foliaceus in vitro and in vivo. J Immunol. 2003 Dec 1; 171(11):6244-50.
  10. Ortiz-Urda S, Lin Q, Yant SR, Keene D, Kay MA, Khavari PA. Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther. 2003 Jul; 10(13):1099-104.
  11. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA. PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum Gene Ther. 2003 Jun 10; 14(9):923-8.
  12. Ortiz-Urda S, Rappersberger K. [New immunosuppressive agents for treating psoriasis]. Hautarzt. 2003 Mar; 54(3):230-6.
  13. Ortiz-Urda S, Lin Q, Green CL, Keene DR, Marinkovich MP, Khavari PA. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest. 2003 Jan; 111(2):251-5.
  14. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, Khavari PA. Stable nonviral genetic correction of inherited human skin disease. Nat Med. 2002 Oct; 8(10):1166-70.
  15. Schmuth M, Yosipovitch G, Williams ML, Weber F, Hintner H, Ortiz-Urda S, Rappersberger K, Crumrine D, Feingold KR, Elias PM. Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis. J Invest Dermatol. 2001 Oct; 117(4):837-47.
  16. Schaeppi H, Bauer JW, Hametner R, Metze D, Ortiz-Urda S, Salmhofer W, Rappersberger K, Hintner H. A localized variant of paraneoplastic pemphigus: acantholysis associated with malignant melanoma. Br J Dermatol. 2001 Jun; 144(6):1249-54.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.